This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
TREMFYA® (guselkumab)
Medical Information
TREMFYA - Latex Content
Last Updated: 09/25/2025
LATEX CONTENT
- Please refer to the local labeling for relevant information regarding approved dosage forms and strengths of TREMFYA.
- The immediate containers or excipients of TREMFYA formulations below are not made with natural rubber latex.1
, 2 - TREMFYA 100 mg/mL in a single-dose One-Press patient-controlled injector.
- TREMFYA 100 mg/mL in a single-dose prefilled pen (TREMFYA PEN).
- TREMFYA 200 mg/2 mL in a single-dose prefilled pen (TREMFYA PEN).
- TREMFYA 100 mg/mL in a single-dose prefilled syringe.
- TREMFYA 200 mg/2 mL in a single-dose prefilled syringe.
- TREMFYA 200 mg/20 mL (10 mg/mL) solution in a single-dose vial.
However, we cannot guarantee that the excipients do not come in contact with latex during the manufacturing or packaging process (eg, latex gloves).1,2
References
| 1 | Data on File. Technical Document - Patient Safety and Compliance Information of Excipients (EXC) and Immediate Containers (IMC) of Tremfya (guselkumab) 200 mg (10 mg/mL) final vialed product (FVP) (IV) v7. Janssen Material Sciences; 2025. |
| 2 |
Would you like to clear and leave your conversation? Message history will be lost.